Drug Profile


Alternative Names: LEO-80190

Latest Information Update: 21 Dec 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LEO Pharma
  • Class Anti-inflammatories; Antipsoriatics; Dihydroxycholecalciferols; Glucocorticoids; Pregnenediones; Small molecules; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 23 Sep 2009 LEO 80190 is no longer licensed to Warner Chilcott
  • 15 Sep 2005 Warner Chilcott has licensed the full portfolio of LEO Pharma's present and future psoriasis therapies in USA
  • 26 May 2005 Phase-II clinical trials in Psoriasis in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top